Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

PaperCitations, authors & open-access status

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 344 citations, 2018 year and bronze oa status.

344
Citations
2018
Year
bronze
OA Status

Related on ScholarIQ

Finn Sellebjerg
Author
Carolyn Young
Author
Multiple Sclerosis Research Studies
Topic
Multiple Sclerosis Research Studies
Topic
Polyomavirus and related diseases
Topic
Amyotrophic Lateral Sclerosis Research
Topic
470M+ articles · free account